Upadacitinib Dosing in Elevated Creatinine
For patients with mild to moderate renal impairment (eGFR ≥30 mL/min/1.73 m²), upadacitinib requires no dose adjustment; for severe renal impairment (eGFR 15-30 mL/min/1.73 m²), the maximum dose is 15 mg daily for atopic dermatitis and 30 mg for induction/15 mg for maintenance in inflammatory bowel disease, while rheumatoid arthritis and other rheumatologic conditions require no adjustment at any level of renal impairment. 1
Dosing Algorithm by Indication and Renal Function
Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Non-radiographic Axial Spondyloarthritis
- eGFR ≥15 mL/min/1.73 m²: No dose adjustment needed 1
- Standard dosing (15 mg daily) can be used across all levels of renal impairment
- This reflects upadacitinib's predominantly hepatic metabolism with only 20% renal excretion 2
Atopic Dermatitis
- eGFR ≥30 mL/min/1.73 m²: No dose adjustment 1
- eGFR 15-30 mL/min/1.73 m²: Maximum 15 mg once daily 3, 1
- Do not use in end-stage renal disease (eGFR <15 mL/min/1.73 m²) 1
Ulcerative Colitis and Crohn's Disease
- eGFR ≥30 mL/min/1.73 m²: No dose adjustment 1
- eGFR 15-30 mL/min/1.73 m²:
- Induction: 30 mg once daily
- Maintenance: 15 mg once daily 1
- Do not use in end-stage renal disease 1
Pharmacokinetic Rationale
The limited impact of renal impairment on upadacitinib exposure is well-characterized. In a dedicated renal impairment study, upadacitinib AUC increased by only 18%, 33%, and 44% in mild, moderate, and severe renal impairment respectively, while maximum concentrations remained essentially unchanged 4. This modest increase reflects the drug's primary hepatic metabolism via CYP3A4 with minimal CYP contribution, and only 24% urinary excretion of unchanged drug 1, 4.
Key Monitoring Considerations
When using upadacitinib in patients with elevated creatinine:
- Baseline assessment: Measure eGFR to categorize renal function accurately 2
- Periodic monitoring: Check creatinine every 1-3 months initially, then every 3 months 2
- Treatment-related increases: JAK inhibitors can cause mild creatinine elevations independent of true renal dysfunction 3
- Real-world evidence: Japanese registry data demonstrated similar effectiveness and safety in patients with eGFR <60 mL/min/1.73 m² compared to those with normal renal function, with physicians appropriately using lower doses (7.5 mg) more frequently in this population 5
Critical Distinctions from Other JAK Inhibitors
Unlike baricitinib (70% renal excretion) and abrocitinib, which require dose reductions starting at eGFR <60 mL/min/1.73 m² and are contraindicated below eGFR 30 mL/min/1.73 m², upadacitinib's predominantly hepatic elimination allows more liberal use in renal impairment 3, 2. This represents a practical advantage when treating patients with comorbid kidney disease.
Contraindications
- Severe hepatic impairment (Child-Pugh C): Absolute contraindication across all indications 3, 1
- End-stage renal disease: Not recommended for atopic dermatitis, ulcerative colitis, or Crohn's disease; has not been studied 1
The evidence consistently supports that elevated creatinine alone, provided eGFR remains ≥15 mL/min/1.73 m², does not preclude upadacitinib use, though indication-specific dose caps apply for severe impairment in atopic dermatitis and inflammatory bowel disease.